Elderly persons are particularly exposed to drug reactions, especially drug interactions subsequent to multiple prescriptions. It is also recognized that the drug risk is the leading hospital risk involving 1 to 10% of all hospitalized patients. An analysis of the avoidable nature of drug reactions leads to consideration of a sequence of 4 events leading to drug exposure: prescription, delivery, administration and compliance. Each event in this sequence corresponds to a distinct person: physician, pharmacist, nurse, patient. This suggests that the prevention of drug reactions in hospitalized elderly persons requires implementation of an "alert-causal attributability-avoidability-prevention" system by the healthcare teams where physicians, pharmacists, and nurses work in close coordination with the patient.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Catalytic Asymmetric Dehydrogenative Si-H/X-H Coupling toward Si-Stereogenic Silanes.
Acc Chem Res
January 2025
Shenzhen Grubbs Institute and Department of Chemistry, Shenzhen Key Laboratory of Small Molecule Drug Discovery and Synthesis, Guangdong Provincial Key Laboratory of Catalysis, Southern University of Science and Technology, Shenzhen, Guangdong 518055, China.
ConspectusChiral organosilicon compounds bearing a Si-stereogenic center have attracted increasing attention in various scientific communities and appear to be a topic of high current relevance in modern organic chemistry, given their versatile utility as chiral building blocks, chiral reagents, chiral auxiliaries, and chiral catalysts. Historically, access to these non-natural Si-stereogenic silanes mainly relies on resolution, whereas their asymmetric synthetic methods dramatically lagged compared to their carbon counterparts. Over the past two decades, transition-metal-catalyzed desymmetrization of prochiral organosilanes has emerged as an effective tool for the synthesis of enantioenriched Si-stereogenic silanes.
View Article and Find Full Text PDFAn anonymized, de-identified registry study protocol to determine the effectiveness and safety of weight loss with enavogliflozin in patients with type 2 diabetes mellitus.
PLoS One
January 2025
Department of Endocrinology and Metabolism, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.
Sodium-glucose co-transporter 2 inhibitors, such as enavogliflozin, offer promising metabolic benefits for patients with type 2 diabetes (T2D), including glycemic control and improved cardiac function. Despite the clinical evidence, real-world evidence is needed to validate their safety and effectiveness. This study aims to evaluate the effects of weight loss and safety of enavogliflozin administration in patients with T2D in a real-world clinical setting over 24 weeks.
View Article and Find Full Text PDFA comprehensive update on the and idiosyncratic adverse drug reactions.
Expert Opin Drug Metab Toxicol
January 2025
Departments of Paediatrics, and Physiology and Pharmacology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
Introduction: . Idiosyncratic adverse drug reactions (IADRs) or drug hypersensitivity reactions (DHRs) represent a major health problem because they are unpredictable and can be severe with potential life-long or even lethal consequences. Their pathophysiology is not clear but thought to be immune mediated supported by the significant statistical association of these reactions with specific alleles of the () gene.
View Article and Find Full Text PDFBottlebrush Pastes as a Platform for Solvent-Free, Injectable, and Shape-Persistent Materials with Tissue-Mimetic Viscoelasticity.
ACS Appl Mater Interfaces
January 2025
Department of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill 27599, United States.
Architecturally hindered crystallization of bottlebrush graft copolymers offers a reaction- and solvent-free pathway for creating injectable elastomers with tissue-mimetic softness. Currently, injectable materials involve solvents and chemical reactions, leading to uncontrolled swelling, leaching of unreacted moieties, and side reactions with tissue. To address this issue, bottlebrush copolymers with a poly(ethylene glycol) (PEG) amorphous block and crystallizable poly(lactic acid) (PLA) grafted chains (A--B) were synthesized, with grafted chains of controlled length arranged along the backbone at controlled spacing.
View Article and Find Full Text PDFPhase 1 Mass Balance Study of Pizuglanstat: An Investigational Hematopoietic Prostaglandin D Synthase Inhibitor.
Clin Pharmacol Drug Dev
January 2025
Taiho Pharmaceutical Co., Ltd., Tokyo, Japan.
Pizuglanstat is a novel hematopoietic prostaglandin D synthase inhibitor and investigational treatment for Duchenne muscular dystrophy. This Phase 1 mass balance study aimed to characterize the absorption, metabolism, and excretion of carbon-14 (C)-labeled pizuglanstat in healthy adults (ClinicalTrials.gov, NCT04825431).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!